Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on inhibiting pro-inflammatory immune cells, a study shows that it is possible to restore the function of certain anti-inflammatory immune cells in a targeted manner. The results pave the way for the development of a therapy that not only works more precisely but is also associated with fewer side effects.